Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:35:23.472Z.
Consensus retrieved: 2026-10-06T08:38:46.609Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:35:23.472Z.
Quote observation: 2026-10-06T18:34:46.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6ac0f7718e38414e938d0d293bbdd3741326646c7ebae4135e2c8e12d98e3a9c
Forward PE Ratio (N/A) = Dated Quote Price ($18.14) / Consensus Forward EPS ($-1.79)
FORWARD PE RATIO
N/A
Aktis Oncology, Inc.
Market Cap
$968.84M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Aktis Oncology, Inc. (AKTS) | $968.84M | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $980.62M | N/A |
| Savara Inc. (SVRA)vs › | $951.27M | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $987.62M | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $988.12M | 35.57 |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $991.81M | N/A |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $941.60M | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $996.44M | N/A |
| Kura Oncology, Inc. (KURA)vs › | $940.12M | N/A |
| Vor Biopharma Inc. (VOR)vs › | $996.87M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $18.14, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.79 | $-1.91 – $-1.46 | 7 | n/m |
| 2027-12-31 | $-2.26 | $-3.01 – $-1.49 | 7 | n/m |
| 2028-12-31 | $-2.47 | $-7.63 – $-0.75 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
